Pyrosequencing Technology as a Method for the Diagnosis of Multiple Endocrine Neoplasia Type 2

Clinical Chemistry

Volumn 50, Issue 3, 2004, Pages 522-529

  Kruckeberg, Kent E ^a   Thibodeau, Stephen N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD SAMPLING; CODON; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; DNA TEMPLATE; EVALUATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIPPLE SYNDROME;

DNA MUTATIONAL ANALYSIS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION, MISSENSE; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES;

BIKINIA LE-TESTUI;

EID: 1542358908     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.027128     Document Type: Article

References (23)

1. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37: 817-27.
2. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995;238:343-6.
3. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 1996; 276:1575-9.
4. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998;83:770-4.
5. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 1997;47:263-8.
6. Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, et al. RET proto-oncogene mutations affectingcodon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 2002;132:952-9 [discussion, 959].
7. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation [Letter]. JAMA 1999;281:1587-8.
8. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, et al. Germline dinucleotide mutation in codon 883 of the RET protooncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997;82:3902-4.
9. Smith DP, Houghton C, Ponder BAJ. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 1997;15: 1213-7.
10. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.
11. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-70.
12. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes [erratum published in Proc Natl Acad Sci USA 1994;91:5217]. Proc Natl Acad Sci USA 1993;90:10325-9.
13. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
14. Pyrosequencing AB. www.pyrosequencing.com (Accessed August 2003)
15. Ahmadian A, Gharizadeh B, Gustafsson AC, Sterky F, Nyren P, Uhlen M, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000;280:103-10.
16. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. The Human Gene Mutation Database (HGMD®): 2003 update. Hum Mutat 2003;21:577-81.
17. Klein I, Esik O, Homolya V, Szeri F, Varadi A. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001;170:661-6.
18. Antinolo G, Marcos I, Femandez RM, Romero M, Borrego S. A novel germline point mutation, c.2304 G→T, in codon 768 of the RET proto-oncogene in a patient with medullary thyroid carcinoma. Am J Med Genet 2002;110:85-7.
19. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000; 128:1052-7 [discussion, 1057-8].
20. Wieser F, Fabjani G, Tempfer C, Schneeberger C, Sator M, Huber J, et al. Analysis of an interleukin-6 gene promoter polymorphism in women with endometriosis by pyrosequencing. J Soc Gynecol Investig 2003;10:32-6.
21. Saeki M, Saito Y, Jinno H, Tohkin M, Kurose K, Kaniwa N, et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin Chem 2003;49:1182-5.
22. Sivertsson A, Platz A, Hansson J, Lundeberg J. Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 2002;48:2164-70.
23. Ferraris A, Rappaport E, Santacroce R, Pollak E, Krantz I, Toth S, et al. Pyrosequencing for detection of mutations in the connexin 26 (GJB2) and mitochondrial 12S RNA (MTRNR1) genes associated with hereditary hearing loss. Hum Mutat 2002;20:312-20.